- Home
- NKSH vs HELP Comparison
NKSH vs HELP Comparison
Compare NKSH & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NKSH | HELP |
|---|---|---|
| Founded | 1891 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.8M | 233.0M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | NKSH | HELP |
|---|---|---|
| Price | $36.55 | $6.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $51.50 |
| AVG Volume (30 Days) | 25.2K | ★ 1.3M |
| Earning Date | 04-23-2026 | 07-01-2026 |
| Dividend Yield | ★ 4.22% | N/A |
| EPS Growth | ★ 100.81 | N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $8,176,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $46.86 | ★ N/A |
| Revenue Growth | ★ 9.39 | N/A |
| 52 Week Low | $27.00 | $3.76 |
| 52 Week High | $40.00 | $8.55 |
Technical Indicators
Market Signals| Indicator | NKSH | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 53.26 | 66.28 |
| Support Level | $35.02 | $5.76 |
| Resistance Level | $38.04 | $6.26 |
| Average True Range (ATR) | 1.21 | 0.44 |
| MACD | 0.11 | 0.22 |
| Stochastic Oscillator | 57.10 | 73.11 |
Price Performance
Historical ComparisonAbout NKSH National Bankshares Inc.
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural loans, commercial real estate, construction loans for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary. The company earns its revenue from interest and fees on loans, non-interest income, and investments.
About HELP Cybin Inc. Common Stock
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.